A 2025 article from SHRM reports a notable increase in the average representation of GLP-1 drugs used for weight loss in total annual claims for employers, increasing from 8.9 percent in 2024 to 10.5 percent in 2025
Risk of lower extremity amputation in patients with type 2 diabetes mellitus and peripheral arterial disease receiving sodium-glucose cotransporter-2 inhibitors versus other medications: a systematic review and meta-analysis of observational cohort studies
Cigna, Blue Cross Blue Shield, Medicare Part D, Medicaid, Aetna, and Amerigroup are among the insurers that might offer coverage with proper medical documentation
Common adverse reactions included nausea, diarrhea, and vomiting
Less commonly, alopecia areata, traction alopecia, diffuse unpatterned alopecia, or an inflammatory or scarring disorder may be responsible
"Ro's direct-to-patient model helps patients achieve outcomes on par with clinical trials and have the best experiences, all at the lowest available prices for FDA-approved treatments." Ro's obesity care formulary is one the most comprehensive of any telehealth company, integrating cash pay and insurance-eligible options that can be delivered to one's home or picked up at a retail pharmacy
